Highline Capital Management, L.P. Biomarin Pharmaceutical Inc Transaction History

Highline Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $40.9 Million - $51.7 Million	-607,021 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $85.7 Million - $100 Million	-1,066,249 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $4.47 Million - $5.24 Million	53,130 Added 5.24%	1,066,249 $94.7 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $21.9 Million - $29 Million	-273,831 Reduced 21.28%	1,013,119 $86.3 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $3.05 Million - $3.44 Million	-32,500 Reduced 2.46%	1,286,950 $125 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $3.46 Million - $4.51 Million	45,550 Added 3.58%	1,319,450 $124 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $98.9 Million - $118 Million	1,273,900 New	1,273,900 $103 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.